Lineage Cell Therapeutics Inc. (LCTX) EPS is poised to hit -0.04 next quarter: How Investors Can Make It Count the Most?
Lineage Cell Therapeutics Inc. (AMEX: LCTX) open the trading on June 09, 2021, with great promise as it jumped 2.18% to $2.81. During the day, the stock rose to $2.91 and sunk to $2.70 before settling in for the price of $2.75 at the close. Taking a more long-term approach, LCTX posted a 52-week range of $0.73-$3.13.
It was noted that the giant of the Healthcare sector posted annual sales growth of -23.60% over the last 5 years. Meanwhile, its Annual Earning per share during the time was 25.40%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -71.00%. This publicly-traded company’s shares outstanding now amounts to $158.72 million, simultaneously with a float of $154.66 million. The organization now has a market capitalization sitting at $442.91 million. At the time of writing, stock’s 50-day Moving Average stood at $2.50, while the 200-day Moving Average is $1.91.
It is quite fundamental to gauge the extent of the productivity of the business which is accounted for 49 workers. It has generated 14,055 per worker during the last fiscal year. Meanwhile, its income per employee was -375,436. The stock had 0.06 Receivables turnover and 0.01 Total Asset turnover. For the Profitability, stocks gross margin was -213.58, operating margin was -3467.01 and Pretax Margin of -2836.22.
Lineage Cell Therapeutics Inc. (LCTX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Lineage Cell Therapeutics Inc.’s current insider ownership accounts for 3.50%, in contrast to 37.20% institutional ownership.
Lineage Cell Therapeutics Inc. (LCTX) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 3/30/2021 suggests? It has posted -$0.01 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$0.03) by $0.02. This company achieved a net margin of -2671.28 while generating a return on equity of -19.74. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
Lineage Cell Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -71.00% and is forecasted to reach -0.21 in the upcoming year.
Lineage Cell Therapeutics Inc. (AMEX: LCTX) Trading Performance Indicators
Let’s observe the current performance indicators for Lineage Cell Therapeutics Inc. (LCTX). It’s Quick Ratio in the last reported quarter now stands at 9.80. The Stock has managed to achieve an average true range (ATR) of 0.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 260.54.
In the same vein, LCTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.09, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.21 at the market close of one year from today.
Technical Analysis of Lineage Cell Therapeutics Inc. (LCTX)
[Lineage Cell Therapeutics Inc., LCTX] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 70.78% While, its Average True Range was 0.19.
Raw Stochastic average of Lineage Cell Therapeutics Inc. (LCTX) in the period of the previous 100 days is set at 79.67%, which indicates a major rise in contrast to 72.86% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 107.39% that was higher than 92.85% volatility it exhibited in the past 100-days period.